CompletedNot Applicable

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

United States1,247 participantsStarted 2024-09-04

Plain-language summary

The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Evidence of 177Lu-PSMA-617 use on or after March 23, 2022 * Date of initiation of 177Lu-PSMA-617 available in the data * Age ≥18 years at index Exclusion criteria: • None

What they're measuring

Number of Patients by Patient Characteristic

Timeframe: Baseline

Mean PSA Level

Timeframe: Baseline

Number of Patients by Number of ARPIs and Taxanes Received Before 177Lu-PSMA-617 Treatment Initiation

Timeframe: Baseline

Number of Patients by Number of Doses of 177Lu-PSMA-617 Treatment From Initiation Until Discontinuation

Timeframe: Up to approximately 2 years

Duration of 177Lu-PSMA-617 Treatment

Timeframe: Up to approximately 2 years

Number and Percentage of Patients Initiating ARPIs, Taxanes, and Other Guideline-recommended Therapies for mCRPC After 177Lu-PSMA-617 Discontinuation

Timeframe: Up to approximately 2 years

Trial details

NCT IDNCT07477756

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-03-14

View on ClinicalTrials.gov More Prostate Cancer trials